Zobrazeno 1 - 10
of 475
pro vyhledávání: '"GLP-1 RA"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety,
Externí odkaz:
https://doaj.org/article/cd3e403ee33d48a886856688d4fd127b
Publikováno v:
Obesities, Vol 4, Iss 3, Pp 256-269 (2024)
Quality glucose-like peptide-1 receptor agonist (GLP-1 RA)-supported digital weight-loss services (DWLSs) have the potential to play a significant role in shifting the alarming global obesity rate. Previous studies have demonstrated various aspects o
Externí odkaz:
https://doaj.org/article/8b70df32524a4b5cae1d887685fd3457
Autor:
Ayse Dudu Altintas Dogan, Thomas Quist Christensen, Torben Tranborg Jensen, Claus Bogh Juhl, Ole Hilberg, Else-Marie Bladbjerg, Søren Hess
Publikováno v:
BMC Research Notes, Vol 17, Iss 1, Pp 1-8 (2024)
Abstract Objective and results description The study objective was to investigate the potential of quantitative measures of pulmonary inflammation by [18 F]Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as a surrogat
Externí odkaz:
https://doaj.org/article/a63946d1f5bc47d98fe58e8a92d1a2df
Autor:
Raveena Kelkar, Nishad A. Barve, Rohan Kelkar, Sanjeev Kharel, Shalmi Khanapurkar, Rukesh Yadav
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionGlucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively used to treat obesity in recent years. These novel drugs are effective at reducing body weight and also the risk of major adverse cardiovascular events in individu
Externí odkaz:
https://doaj.org/article/0600a3d9d53c4cff9a4723986102755e
Autor:
Hannah Moll, Eliane Frey, Philipp Gerber, Bettina Geidl, Marco Kaufmann, Julia Braun, Felix Beuschlein, Milo A. Puhan, Henock G. Yebyo
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102661- (2024)
Summary: Background: The benefit of Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) in weight reduction against potential harms remains unclear. This study aimed at evaluating the benefit-harm balance of initiating GLP-1 RAs versus placebo fo
Externí odkaz:
https://doaj.org/article/5298966685584d538c98ee0ec3adb8a6
Autor:
Oliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández-Fernández, Thomas Forst, Juan-Pablo Frias, James R. Gavin, Francesco Giorgino, Per-Henrik Groop, Hiddo J. L. Heerspink, Stephan Herzig, Michael Hummel, George Huntley, Mahmoud Ibrahim, Baruch Itzhak, Stephan Jacob, Linong Ji, Mikhail Kosiborod, Nebosja Lalic, Sofia Macieira, Rayaz A. Malik, Boris Mankovsky, Nikolaus Marx, Chantal Mathieu, Timo D. Müller, Kausik Ray, Helena W. Rodbard, Peter Rossing, Lars Rydén, Petra-Maria Schumm-Draeger, Peter Schwarz, Jan Škrha, Frank Snoek, Frank Tacke, Bruce Taylor, Britta Tendal Jeppesen, Solomon Tesfaye, Pinar Topsever, Tina Vilsbøll, Xuefeng Yu, Eberhard Standl
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-17 (2024)
Abstract The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exch
Externí odkaz:
https://doaj.org/article/167ffccba8024cf1934fce0e0b20bdf0
Autor:
Bochra Zareini, Katrine Kold Sørensen, Ulrik Pedersen‐Bjergaard, Emil Loldrup Fosbøl, Lars Køber, Christian Torp‐Pedersen
Publikováno v:
Journal of Diabetes, Vol 16, Iss 6, Pp n/a-n/a (2024)
Abstract Aim To compare the cardiovascular preventive effect associated with glucagon‐like‐peptide‐1 receptor agonists (GLP‐1 RA) versus dipeptidyl peptidase‐4 inhibitors (DPP‐4i) according to the achieved target level of glycated hemoglo
Externí odkaz:
https://doaj.org/article/60f4e222b6ce4efc87dfce24ac258d90
Autor:
Leigh Perreault, Bryan C. Bergman
Publikováno v:
Journal of Diabetes, Vol 16, Iss 6, Pp n/a-n/a (2024)
Highlights Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon. During this time of global shortage of glucagon‐like peptide‐1 recept
Externí odkaz:
https://doaj.org/article/a01f19bc927748269ce1a07998c04582
Autor:
Luis A. Rodriguez, Holly Finertie, Romain S. Neugebauer, Bennett Gosiker, Tainayah W. Thomas, Andrew J. Karter, Lisa K. Gilliam, Caryn Oshiro, Jaejin An, Gregg Simonson, Andrea E. Cassidy-Bushrow, Sarah Dombrowski, Margaret Nolan, Patrick J. O'Connor, Julie A. Schmittdiel
Publikováno v:
The Lancet Regional Health. Americas, Vol 34, Iss , Pp 100759- (2024)
Summary: Background: Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) improve cardiorenal outcomes in patients with type 2 diabetes. Equitable use of SGLT2i and GLP-1 RA has the potential to
Externí odkaz:
https://doaj.org/article/a33b4e7746464bb68c532e38869f1f88
Autor:
Xiang Yan, Jianhua Ma, Yan Liu, Xuhong Wang, Sheli Li, Shuang Yan, Zhaohui Mo, Yikun Zhu, Jingna Lin, Jie Liu, Ying Jia, Li Liu, Ke Ding, Michael Xu, Zhiguang Zhou
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 47, Iss , Pp 101101- (2024)
Summary: Background: Type 2 diabetes (T2DM) remains a challenge to treat despite the expansion of various therapeutic classes. Visepegenatide (PB-119) is a once a week, subcutaneous, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection witho
Externí odkaz:
https://doaj.org/article/bd2bbfb7c81a406ca63de93afe916cbe